bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Volume
Czytanie zajmuje mniej niż 1 minutę
On November 5, 2025, bioAffinity Technologies, Inc. announced a significant increase in CyPath® Lung test volume.
Key Highlights:
- October test volume rose 111% over the 2025 monthly average.
- Third-quarter sales volume increased 95% from the previous quarter.
- Medical practices with multiple orders grew 106% in Q3.
- Steady adoption reflects growing clinical trust in CyPath® Lung.
- Company aims to change the standard of care in early lung cancer detection.
Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 8-K - Nov. 05, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.